Nanjing Kefeiping Shenghui Pharmaceutical

Nanjing Kefeiping Pharmaceutical is a Chinese biopharmaceutical company dedicated to the research, development, and commercialization of innovative small molecule therapeutics. The company primarily focuses on digestive system disorders, cardiovascular diseases, and cerebrovascular conditions. Its lead product, Keverprazan (Kevenezan), is a potassium-competitive acid blocker (P-CAB) that received marketing approval in China for treating duodenal ulcers and reflux esophagitis. Kefeiping maintains an integrated business model encompassing drug discovery, clinical development, and large-scale manufacturing. The company aims to address significant unmet medical needs through its pipeline of innovative drugs and high-end generic formulations. It operates several subsidiaries, including Nanjing Kefeiping Shenghui Pharmaceutical, which supports its commercial and operational activities.